The mission of MultiplexDX is to eliminate cancer misdiagnosis by creating reliable, 100% accurate, quantitative and affordable diagnostic tests. MDX’s IP-based solutions combine visualization and sequencing technologies to quantify 7 or more cancer markers to give each diagnosis a specific “barcode,” which will indicate not only the cancer type but also the duration of personalized treatment for that cancer. As their name suggests, they also use multiplexing; cross-testing and verifying the same result from at least two independent sources. By embedding numbers into pictures and vice-versa, their diagnostics shed light on the patient’s set of cancer markers and profile, enabling oncologists to make evidence-based decisions and prescribe treatment quickly, directly and more accurately.
Main features At least one-month room temperature stability Improved sensitivity of proprietary RdRP and E assays Multiplexed version With RNase P assay as an internal control SARS-CoV-2 full genomic RNA spiked with human RNA used as a positive control 100% clinical accuracy Ultrasensitive limit of detection of 2 RNA copies/rxn for all targets (SARS-CoV-2, IAV and IBV) 100% specific for SARS-CoV-2, and WH…
